BACKGROUND: Treatment with GH promotes linear growth and decreases body fat in patients with isolated GH deficiency (GHD). However, few studies have analyzed how GH replacement modifies ghrelin levels and the adipokine profile and the relationship of these modifications with the metabolic changes. AIMS: To analyze the eventual differences between serum levels of leptin, leptin soluble receptor (sOBR), resistin, adiponectin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), total (TG) and acylated ghrelin (AG) and lipid and glycemic profiles in children with GHD, as well as to determine the effect of GH replacement on these parameters during the first year of therapy. SUBJECTS AND METHODS: Thirty pre-pubertal (Tanner stage I) GHD children and 30 matched controls were enrolled. Children with GHD were studied before and after 6 and 12 months of GH treatment. Weight, height, BMI, fasting glucose, insulin, lipid profile and serum levels of adipokines and ghrelin were studied at every visit. Adi - pokines, insulin and ghrelin levels were determined by using commercial radio- and enzymoimmunoassays. RESULTS: At baseline children with GHD had significantly higher sOBR (p<0.01) and adiponectin (p<0.01) levels than controls. Treatment with GH resulted in a decline in leptin (p<0.05) and TG (p<0.001) levels, an increase of homeostasis model assessment index and restored IGF-I levels (p<0.001). CONCLUSIONS: These data indicate that GH replacement has a negative effect on leptin levels and may also produce a slight unfavorable effect on carbohydrate metabolism. In addition, the changes observed in the adipokine profile appear to be independent of body mass index.
RCT Entities:
BACKGROUND: Treatment with GH promotes linear growth and decreases body fat in patients with isolated GH deficiency (GHD). However, few studies have analyzed how GH replacement modifies ghrelin levels and the adipokine profile and the relationship of these modifications with the metabolic changes. AIMS: To analyze the eventual differences between serum levels of leptin, leptin soluble receptor (sOBR), resistin, adiponectin, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), total (TG) and acylated ghrelin (AG) and lipid and glycemic profiles in children with GHD, as well as to determine the effect of GH replacement on these parameters during the first year of therapy. SUBJECTS AND METHODS: Thirty pre-pubertal (Tanner stage I) GHD children and 30 matched controls were enrolled. Children with GHD were studied before and after 6 and 12 months of GH treatment. Weight, height, BMI, fasting glucose, insulin, lipid profile and serum levels of adipokines and ghrelin were studied at every visit. Adi - pokines, insulin and ghrelin levels were determined by using commercial radio- and enzymoimmunoassays. RESULTS: At baseline children with GHD had significantly higher sOBR (p<0.01) and adiponectin (p<0.01) levels than controls. Treatment with GH resulted in a decline in leptin (p<0.05) and TG (p<0.001) levels, an increase of homeostasis model assessment index and restored IGF-I levels (p<0.001). CONCLUSIONS: These data indicate that GH replacement has a negative effect on leptin levels and may also produce a slight unfavorable effect on carbohydrate metabolism. In addition, the changes observed in the adipokine profile appear to be independent of body mass index.
Authors: M Angulo; M Castro-Magana; B Mazur; J A Canas; P M Vitollo; M Sarrantonio Journal: J Pediatr Endocrinol Metab Date: 1996 May-Jun Impact factor: 1.634
Authors: D A M Festen; A van Toorenenbergen; H J Duivenvoorden; A C S Hokken-Koelega Journal: J Clin Endocrinol Metab Date: 2007-01-30 Impact factor: 5.958
Authors: Juan-Pablo del Rincon; Keiji Iida; Bruce D Gaylinn; Carrie E McCurdy; J Wayne Leitner; Linda A Barbour; John J Kopchick; Jacob E Friedman; Boris Draznin; Michael O Thorner Journal: Diabetes Date: 2007-03-15 Impact factor: 9.461
Authors: Lora C Bailey-Downs; Danuta Sosnowska; Peter Toth; Matthew Mitschelen; Tripti Gautam; Jim C Henthorn; Praveen Ballabh; Akos Koller; Julie A Farley; William E Sonntag; Anna Csiszar; Zoltan Ungvari Journal: J Gerontol A Biol Sci Med Sci Date: 2011-11-10 Impact factor: 6.053
Authors: E Gómez-Guzmán; M D Cañete; R Valle-Martos; R Cañete; M Valle; L Jiménez-Reina; J Caballero-Villarraso Journal: Front Pediatr Date: 2018-06-19 Impact factor: 3.418
Authors: Katarzyna Adamczewska; Zbigniew Adamczewski; Andrzej Lewiński; Renata Stawerska Journal: Front Endocrinol (Lausanne) Date: 2022-03-24 Impact factor: 5.555